E-viri
PDF
Recenzirano
Odprti dostop
-
Yap, Timothy A; Bjerke, Lynn; Clarke, Paul A; Workman, Paul
Current opinion in pharmacology, 08/2015, Letnik: 23Journal Article
Highlights • PI3K is an important target for innovative anticancer drug development and precision medicine. • Over 30 small molecule PI3K inhibitors are currently in clinical trial testing. • These drugs include dual PI3K/mTOR, pan-Class I PI3K and isoform-selective PI3K inhibitors. • The PI3Kδ inhibitor idelalisib has received FDA approval for the treatment of B-cell malignancies. • Drug resistance, patient selection and development of targeted combinations remain challenges.
